Li Dong, Ho Vikki, Teng Chiao-Fang, Tsai Hung-Wen, Liu Yuanyuan, Bae Sarah, Ajoyan Harout, Wettengel Jochen M, Protzer Ulrike, Gloss Brian S, Rockett Rebecca J, Al Asady Rafid, Li Jane, So Simon, George Jacob, Douglas Mark W, Tu Thomas
Storr Liver Centre, The Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, Westmead, NSW, Australia.
Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Emerg Microbes Infect. 2025 Dec;14(1):2450025. doi: 10.1080/22221751.2025.2450025. Epub 2025 Jan 13.
Hepatitis B virus (HBV) DNA integration into the host cell genome is reportedly a major cause of liver cancer, and a source of hepatitis B surface antigen (HBsAg). High HBsAg levels can alter immune responses which therefore contributes to the progression of HBV-related disease. However, to what extent integration leads to the persistent circulating HBsAg is unclear. Here, we aimed to determine if the extent of HBV DNA integration is associated with the persistence of circulating HBsAg in people exposed to HBV. We established a digital droplet quantitative inverse PCR (dd-qinvPCR) method to quantify integrated HBV DNA in patients who had been exposed to HBV (anti-HBc positive and HBeAg-negative). Total DNA extracts from both liver resections (n = 32; 14 HBsAg-negative and 18 HBsAg-positive) and fine-needle aspirates (FNA, n = 10; 2 HBsAg-negative and 8 HBsAg-positive) were analysed. Using defined samples for assay establishment, we showed that dd-qinvPCR could detect integrations within an input of <80 cells. The frequency of integrated HBV DNA in those who had undergone HBsAg loss (n = 14, mean ± SD of 1.514 × 10± 1.839 × 10 integrations per cell) was on average 9-fold lower than those with active HBV infection (n = 18, 1.16 × 10± 1.76 × 10 integrations per cell; = 0.0179). In conclusion, we have developed and validated a highly precise, sensitive and quantitative PCR-based method for the quantification of HBV integrations in clinical samples. Natural clearance of HBV is associated with fewer viral integrations. Future studies are needed to determine if dynamics of integrated HBV DNA can inform the development of curative therapies.
据报道,乙型肝炎病毒(HBV)DNA整合到宿主细胞基因组中是肝癌的主要原因,也是乙型肝炎表面抗原(HBsAg)的一个来源。高HBsAg水平可改变免疫反应,因此促进了HBV相关疾病的进展。然而,整合在多大程度上导致循环HBsAg持续存在尚不清楚。在这里,我们旨在确定HBV DNA整合程度是否与接触HBV人群中循环HBsAg的持续存在有关。我们建立了一种数字液滴定量反向PCR(dd-qinvPCR)方法,用于量化接触过HBV的患者(抗-HBc阳性且HBeAg阴性)体内整合的HBV DNA。对肝切除术(n = 32;14例HBsAg阴性和18例HBsAg阳性)和细针穿刺抽吸物(FNA,n = 10;2例HBsAg阴性和8例HBsAg阳性)的总DNA提取物进行了分析。使用定义的样本进行检测方法的建立,我们表明dd-qinvPCR可以在输入少于80个细胞的情况下检测到整合。HBsAg消失的患者(n = 14,平均±标准差为每细胞1.514×10±1.839×10次整合)中整合HBV DNA的频率平均比活动性HBV感染患者(n = 18,每细胞1.16×10±1.76×10次整合;P = 0.0179)低9倍。总之,我们开发并验证了一种基于PCR的高度精确、灵敏且定量的方法,用于量化临床样本中的HBV整合。HBV的自然清除与较少的病毒整合相关。未来需要开展研究以确定整合的HBV DNA动态变化是否可为治愈性疗法的开发提供信息。